Vydura (rimegepant) makes progress in UK health technology assessments PRODROME shows benefits of taking ubrogepant during prodromal phase of migraine ELEVATE study confirms atogepant efficacy after previous treatment failures Zavegepant effective in acute migraine treatment irrespective of attack frequency or aura Hypertension data suggest need for blood pressure monitoring with erenumab No evidence of ‘wearing off’ with fremanezumab or eptinezumab Real world study indicates gepant safety and efficacy in under-18s Non-ictal allodynia predicts galcanezumab response

Partnership & Outreach

Through its unique global network of researchers and clinicians, the CGRP Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of the burden, disability and cost associated with migraine.

Educational Partners and Supporters (others pending) Amgen

Amgen

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2023 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |